てんかん(癲癇)の世界市場インサイト・疫学分析・市場予測

◆英語タイトル:Epilepsy Market Insight, Epidemiology and Market Forecast
◆商品コード:DELV803009
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2018年3月
◆ページ数:127
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2営業日以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD6,250 ⇒換算¥687,500見積依頼/購入/質問フォーム
Site Price(同一事業所内共有可)USD12,500 ⇒換算¥1,375,000見積依頼/購入/質問フォーム
Enterprise Price(同一法人内共有可)USD18,750 ⇒換算¥2,062,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s ‘Epilepsy – Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Epilepsy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Epilepsy from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Epilepsy – Disease Understanding and Treatment Algorithm
The DelveInsight Epilepsy market report gives the thorough understanding of the Epilepsy by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Epilepsy in the US, Europe, and Japan.
Epilepsy Epidemiology
The Epilepsy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by sex-specific [Male and Female] and sub-type [Focal/ Partial, Generalized, Unclassified]. The report further covers prevalence of Tuberous Sclerosis Complex (TSC) associated Epilepsy.
According to DelveInsight, the prevalent cases of Epilepsy was 7,649,695 in 2016 in 7 MM and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of Epilepsy with 4,007,026 prevalent cases in 2016 followed by Germany.

Epilepsy Drug Chapters
This segment of the Epilepsy report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Currently, there are approximately 50 drugs in market for Epilepsy out of which 50% have gone off patent. This report includes detailed chapters of marketed along with the promising upcoming therapies.

Epilepsy Market Outlook
The Epilepsy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Epilepsy market is expected to grow during the forecasted period of 2018-2027 at a CAGR of XX% owing to the launch of nine drugs (presently in Phase III). Epilepsy Therapeutics market has seen a global sales of 5.4 billion in 2016. The three best selling drugs were Vimpat (UCB), Lamictal (Glaxosmithkline) and Keppra (UCB) with Vimpat recording highest sales of 895 million in 2016.

Epilepsy Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Epilepsy Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Epilepsy Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Epilepsy Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Epilepsy market
• Organize sales and marketing efforts by identifying the best opportunities for Epilepsy market
• To understand the future market competition in the Epilepsy market.

【レポートの目次】

1. Report Summary 1
2. Epilepsy Disease Background 10
2.1. Introduction 10
2.2. Causes 11
2.3. Symptoms 11
2.4. Classification 12
2.5. Risk factors 16
2.6. Diagnosis 16
2.7. TSC Mutations in Epilepsy 18
2.8. Current Treatment & Medical Practices 19
3. Epidemiology and Patient Population 20
3.1. Key Points 20
3.2. United States 21
3.2.1. Prevalence of Epilepsy in United States 21
3.2.2. Gender specific prevalence in United States 23
3.2.3. Sub-type specific prevalence in United States 24
3.2.4. Prevalence of TSC associated Epilepsy in the United States 25
3.3. Germany 26
3.3.1. Prevalence of Epilepsy in Germany 26
3.3.2. Gender specific prevalence in Germany 28
3.3.3. Sub-type specific prevalence in Germany 29
3.3.4. Prevalence of TSC associated Epilepsy in the Germany 30
3.4. France 31
3.4.1. Prevalence of Epilepsy in France 31
3.4.2. Gender specific prevalence in France 33
3.4.3. Sub-type specific prevalence in France 34
3.4.4. Prevalence of TSC associated Epilepsy in the France 35
3.5. Italy 36
3.5.1. Prevalence of Epilepsy in Italy 36
3.5.2. Gender specific prevalence in Italy 38
3.5.3. Sub-type specific prevalence in Italy 39
3.5.4. Prevalence of TSC associated Epilepsy in the Italy 40
3.6. Spain 41
3.6.1. Prevalence of Epilepsy in Spain 41
3.6.2. Gender specific prevalence in Spain 43
3.6.3. Sub-type specific prevalence in Spain 44
3.6.4. Prevalence of TSC associated Epilepsy in the Spain 45
3.7. United Kingdom 46
3.7.1. Prevalence of Epilepsy in United Kingdom 46
3.7.2. Gender specific prevalence in United Kingdom 48
3.7.3. Sub-type specific prevalence in United Kingdom 49
3.7.4. Prevalence of TSC associated Epilepsy in the UK 50
3.8. Japan 51
3.8.1. Prevalence of Epilepsy in Japan 51
3.8.2. Gender specific prevalence in Japan 53
3.8.3. Sub-type specific prevalence in Japan 54
4. Treatment Algorithm 55
4.1. NICE Guidelines 56
4.2. Treatment options in the management of Epilepsy in patients with TSC 59
4.3. Epilepsy treatment in TSC: Clinical Recommendations 60
5. Unmet Needs 62
6. Competitive Landscape-Marketed Drugs 63
6.1. Vimpat: UCB 63
6.1.1. Drug Description 63
6.1.2. Product Profile 65
6.1.3. Vimpat Sales 65
6.2. Lyrica: Pfizer 66
6.2.1. Drug Description 66
6.2.2. Product Profile 67
6.2.3. Lyrica Sales 67
6.3. Banzel: Eisai 68
6.3.1. Drug Description 68
6.3.2. Product Profile 69
6.3.3. Banzel Sales 69
6.4. Briviact: UCB Pharma 70
6.4.1. Drug Description 70
6.4.2. Product Profile 71
6.4.3. Briviact Sales 71
6.5. Keppra: UCB 72
6.5.1. Drug Description 72
6.5.2. Product Profile 73
6.5.3. Keppra Sales 73
6.6. Keppra XR (levetiracetam XR): UCB 74
6.6.1. Drug Description 74
6.6.2. Product Profile 75
6.6.3. Keppra Sales 75
6.7. Topamax: Janssen 76
6.7.1. Drug Production 76
6.7.2. Product Profile 77
6.7.3. Topamax Sales 77
6.8. Lamictal: GlaxoSmithKline 78
6.8.1. Drug Description 78
6.8.2. Product Profile 79
6.8.3. Lamictal Sales 79
6.9. Neurontin: Pfizer 80
6.9.1. Drug Description 80
6.9.2. Product Profile 80
6.9.3. Neurontin Sales 81
6.10. Zonegran: Eisai 82
6.10.1. Drug Description 82
6.10.2. Product Profile 84
6.10.3. Zonegran Sales 84
6.11. Trileptal: Novartis 85
6.11.1. Drug Description 85
6.11.2. Product Profile 86
6.11.3. Trileptal Sales 86
6.12. Zebinix (Aptiom): Dainippon Sumitomo Pharma/Eisai 87
6.12.1. Drug Description 87
6.12.2. Product Profile 88
6.12.3. Zebinix (Aptiom) Sales 88
6.13. Fycompa: Eisai 89
6.13.1. Drug Description 89
6.13.2. Product Profile 90
6.13.3. Fycompa Sales 90
7. Emerging Therapies 91
7.1. Upcoming Drugs 91
7.2. Epidiolex: GW Pharmaceuticals 92
7.2.1. Product Description 92
7.2.2. Research and Development 93
7.2.3. Product Development Activities 95
7.3. Fintepla: Zogenix 97
7.3.1. Product Description 97
7.3.2. Research and Development 97
7.3.3. Product Development Activities 98
7.4. PF-06372865: Pfizer 99
7.4.1. Product Description 99
7.4.2. Research & Development 99
7.5. UCB0942: UCB 100
7.5.1. Product Description 100
7.5.2. Research & Development 100
7.6. Ganaxolone: Marinus Pharmaceuticals 101
7.6.1. Product Description 101
7.6.2. Research & Development 101
7.6.3. Product Development Activities 102
7.7. SAGE-547: Sage Therapeutics 103
7.7.1. Product Description 103
7.7.2. Research and Development 103
7.7.3. Product Development Activities 104
7.8. Triheptanoin: Ultragenyx Pharmaceutical 105
7.8.1. Product Description 105
7.8.2. Research and Development 105
7.8.3. Product Development Activities 106
7.9. CPP-115: Catalyst Pharmaceuticals 108
7.9.1. Product Description 108
7.9.2. Research and development 108
7.9.3. Product Development Activities 108
7.10. ZYN002: Zynerba Pharma 110
7.10.1. Product Description 110
7.10.2. Research and Development 110
7.10.3. Product Development Activities 111
8. Market Size of Epilepsy 112
9. Global Market Size 112
9.1. Key Findings 112
9.2. Market Size of Top-10 Products (2016) 113
9.3. Market Size of Top-10 Products (2025) 114
9.4. Upcoming Drug Launches-Uptake 115
10. United States 116
10.1. Market Outlook of Epilepsy in United States 116
11. EU5 118
11.1. Market outlook of Epilepsy in EU5 118
12. Japan 120
12.1. Market outlook of Epilepsy in Japan 120
13. Market Drivers 122
14. Market Barriers 123
15. Appendix 124
15.1. Report Methodology 124
16. Consulting Services 126
17. Disclaimer 127
18. About DelveInsight 127

Table 1: Prevalent Population of Epilepsy in the United States (2016-2027) 22
Table 2: Gender specific Prevalent Population of Epilepsy in the United States (2016-2027) 23
Table 3: Sub-type specific Prevalent Population of Epilepsy in the United States (2016-2027) 24
Table 4: Prevalence of TSC associated Epilepsy in the United States (2016-2027) 25
Table 5: Prevalent Population of Epilepsy in the Germany (2016-2027) 27
Table 6: Gender specific Prevalent Population of Epilepsy in the Germany (2016-2027) 28
Table 7: Sub-type specific Prevalent Population of Epilepsy in the United States (2016-2027) 29
Table 8: Prevalence of TSC associated Epilepsy in the Germany (2016-2027) 30
Table 9: Prevalent Population of Epilepsy in the France (2016-2027) 32
Table 10: Gender specific Prevalent Population of Epilepsy in the France (2016-2027) 33
Table 11: Sub-type specific Prevalent Population of Epilepsy in the France (2016-2027) 34
Table 12: Prevalence of TSC associated Epilepsy in the France (2016-2027) 35
Table 13: Prevalent Population of Epilepsy in the Italy (2016-2027) 37
Table 14: Gender specific Prevalent Population of Epilepsy in the Italy (2016-2027) 38
Table 15: Sub-type specific Prevalent Population of Epilepsy in the Italy (2016-2027) 39
Table 16: Prevalence of TSC associated Epilepsy in the Italy (2016-2027) 40
Table 17: Prevalent Population of Epilepsy in the Spain (2016-2027) 42
Table 18: Gender specific Prevalent Population of Epilepsy in the Spain (2016-2027) 43
Table 19: Sub-type specific Prevalent Population of Epilepsy in the Spain (2016-2027) 44
Table 20: Prevalence of TSC associated Epilepsy in the Spain (2016-2027) 45
Table 21: Prevalent Population of Epilepsy in the United Kingdom (2016-2027) 47
Table 22: Gender specific Prevalent Population of Epilepsy in the UK (2016-2027) 48
Table 23: Sub-type specific Prevalent Population of Epilepsy in the UK (2016-2027) 49
Table 24: Prevalence of TSC associated Epilepsy in the UK (2016-2027) 50
Table 25: Prevalent Population of Epilepsy in the Japan (2016-2027) 52
Table 26: Gender specific Prevalent Population of Epilepsy in the Japan (2016-2027) 53
Table 27: Sub-type specific Prevalent Population of Epilepsy in the Japan (2016-2027) 54
Table 28: Upcoming therapies and their launch dates (2016-2027) 91
Table 29: Global Market Size of Epilepsy in USD, Million (2016-2027) 112
Table 30: Market Size of Top-10 Products (2016) 113
Table 31: Market Size of Top-10 Products (2025) 114
Table 32: Upcoming Drug Launches-Uptake Graph (2016-2027) 115
Table 33: United States Market Size of Epilepsy in USD, Million (2016-2027) 117
Table 34: EU5 Market Size of Epilepsy in USD, Million (2016-2027) 119
Table 35:Japan Market Size of Epilepsy in USD, Million (2016-2027) 121


Figure 1: ILAE 2017 Classification of Seizure Types Basic Version 12
Figure 2: ILAE 2017 Classification of Seizure Types Extended Version 13
Figure 3: Classification of Epilepsy 14
Figure 4: Prevalent Population of Epilepsy in the United States (2016-2027) 22
Figure 5: Gender specific Prevalent Population of Epilepsy in the United States (2016-2027) 23
Figure 6: Sub-type specific Prevalent Population of Epilepsy in the United States (2016-2027) 24
Figure 7: Prevalence of TSC associated Epilepsy in the United States (2016-2027) 25
Figure 8: Prevalent Population of Epilepsy in the Germany (2016-2027) 27
Figure 9: Gender specific Prevalent Population of Epilepsy in the Germany (2016-2027) 28
Figure 10: Sub-type specific Prevalent Population of Epilepsy in the Germany (2016-2027) 29
Figure 11: Prevalence of TSC associated Epilepsy in the Germany (2016-2027) 30
Figure 12: Prevalent Population of Epilepsy in the France (2016-2027) 32
Figure 13: Gender specific Prevalent Population of Epilepsy in the France (2016-2027) 33
Figure 14: Sub-type specific Prevalent Population of Epilepsy in the France (2016-2027) 34
Figure 15: Prevalence of TSC associated Epilepsy in the France (2016-2027) 35
Figure 16: Prevalent Population of Epilepsy in the Italy (2016-2027) 37
Figure 17: Gender specific Prevalent Population of Epilepsy in the Italy (2016-2027) 38
Figure 18: Sub-type specific Prevalent Population of Epilepsy in the Italy (2016-2027) 39
Figure 19: Prevalence of TSC associated Epilepsy in the Italy (2016-2027) 40
Figure 20: Prevalent Population of Epilepsy in the Spain (2016-2027) 42
Figure 21: Gender specific Prevalent Population of Epilepsy in the Spain (2016-2027) 43
Figure 22: Sub-type specific Prevalent Population of Epilepsy in the Spain (2016-2027) 44
Figure 23: Prevalence of TSC associated Epilepsy in the Spain (2016-2027) 45
Figure 24: Prevalent Population of Epilepsy in the United Kingdom (2016-2027) 47
Figure 25: Gender specific Prevalent Population of Epilepsy in the UK (2016-2027) 48
Figure 26: Sub-type specific Prevalent Population of Epilepsy in the UK (2016-2027) 49
Figure 27: Prevalence of TSC associated Epilepsy in the UK (2016-2027) 50
Figure 28: Prevalent Population of Epilepsy in the Japan (2016-2027) 52
Figure 29: Gender specific Prevalent Population of Epilepsy in the Japan (2016-2027) 53
Figure 30: Sub-type specific Prevalent Population of Epilepsy in the Japan (2016-2027) 54
Figure 31: Seizure-Types and Choice of Anti-Epileptic Drugs (AEDs) 55
Figure 32: Vimpat: Historical Sales (2012-2016) 65
Figure 33: Lyrica: Historical Sales (2012-2016) 67
Figure 34: Banzel: Historical Sales (2012-2016) 69
Figure 35:: Keppra: Historical Sales (2012-2016) 73
Figure 36: Keppra: Historical Sales (2012-2016) 75
Figure 37: Topamax: Historical Sales (2012-2016) 77
Figure 38:: Lamictal: Historical Sales (2012-2016) 79
Figure 39: Neurontin: Historical Sales (2012-2016) 81
Figure 40: Zonegran: Historical Sales (2012-2016) 84
Figure 41: Trileptal: Historical Sales (2012-2016) 86
Figure 42: Zebinix: Historical Sales (2012-2016) 88
Figure 43: Fycompa: Historical Sales (2012-2016) 90
Figure 44: Global Market size of Epilepsy in USD, Millions (2016-2027) 112
Figure 45: Market Size of Top-10 Products (2016) 113
Figure 46: Market Size of Top-10 Products (2025) 114
Figure 47: Upcoming Drug Launches-Uptake Graph (2016-2027) 115
Figure 48: United States Market size of Epilepsy in USD, Millions (2016-2027) 117
Figure 49: EU5 Market size of Epilepsy in USD, Millions (2016-2027) 119
Figure 50:Japan Market size of Epilepsy in USD, Millions (2016-2027) 121


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ てんかん(癲癇)の世界市場インサイト・疫学分析・市場予測(Epilepsy Market Insight, Epidemiology and Market Forecast )]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆